| Abstract: |
Results.Antiinflammatory activity:The obtained results (Table 12) revealed that all the test compounds as well as the standard drug(diclofenac sodium) possess a significantantiinflammatory activity when compared with the control group(given only carrageenin) during the entire period of the experiment. After one hour the rank order of potency as antiinflammatory was as follows;Compound number XIVb2> XVIb1> VIII> XIVa1> XVIa2, standard> XIIIb1Whereas the rank order of potency after two hours was as follows;Compound number VIII, XIVa1> XVIb1> XVIa2>standard> XIVb2, XIIIb1while at the end of the experiment the rank order of potency was as follows; Compound number XIVa1> VIII, XVIb1> XIIIb1, ,XIVb2, XVIa2> standardindicating that all the test compounds possess antiinflammatory activity more than the standard drug especially compound number (XIVa1) where its antiinflammatory activity was more significantly greater than the standard drug and the other test compounds. However compound (XIVb2) appears toxic since one rat died after two hours and two more rats died after three hours so the dose of this compound should be reduced.Table(12); the antiinflammatory activity of the test compounds as well as diclofenac sodium given intraperitoneally in a dose of 1.0 mg/100gm. of rats.(Mean S.E) n= 5 ratsGrouptreatment Initial thickness of rate paws(mm). Initial thickness of rate paw(mm) afterOne hourTwo hoursThree hours1 Control (carrageenin only) 5.5 a ±0.54 7.25 a ±0.25 7.75 a ±0.47 6.37 a ±0.472 Compound no VIII (1.0mg/100gm.b.wt) +carrageenin 4.6 a ±0.23 4.25 bc ±0.14 3.75 c ±0.14 3.37 bc ±0.233 Compound noXIIIb1 (1.0mg/100gm.b.wt) +carrageenin 5.25 a ±0.62 5.25 b ±0.47 4.5 c ±0.28 4.0 bc ±0.284 Compound no XIVa1 (1.0mg/100gm.b.wt) +carrageenin 5.5 a ±0.28 4.37 bc ±0.2 3.75 c ±0.14 3.12 c ±0.125 Compound no XIVb2 (1.0mg/100gm.b.wt) +carrageenin 4.75 a ±0.77 3.8 c±0.6 5.25 b ±0.5 4.0 bc ±0.26 Compound no XVIa2 (1.0mg/100gm.b.wt) +carrageenin 4.62 a ±0.23 4.4 bc ±0.24 4.0 c±0.2 4.0 bc ±0.287 Compound noXVIb1 (1.0mg/100gm.b.wt) +carrageenin 4.8 a ±0.14 3.87 c ±0.12 3.87 c ±0.12 3.37 bc ±0.238 Diclofenac sodium(standard) (1.0mg/100gm.b.wt) +carrageenin 5.7 a ±0.25 4.5 bc ±0.28 4.25 c ±0.25 4.1 b±0.1Means within the same column bearing different superscripts are significantly at(p ).Antihypertensive activityTable (13) illustrates that all the test compounds together with the standard drug significantly lowered the mean arterial blood pressure of phenobarbitone anaesthetized dogs, with the rank order of potency as follows. Standard drug>Vh>Vd>Ve>Vb. The antihypertensive activity of the standard drug was more significantly higher than that of the test compoundsTable(13);The antihypertensive activity of the test compounds and standard (doxazosinmesylate) in phenobarbitone anaesthetized dogs(Mean S.E) n= 4 dogsGroup Treatment Mean arterial blood pressureControlMedodrine HCl 2.5 mg/20kg.of dog.167.5±1.42 aVb2.5 mg compound (Vb)/20kg. of dog.150±2.01 bVd2.5 mg compound (Vd)/20kg. of dog.148.5±1.42 bVe2.5 mg compound (Ve)/20kg. of dog.149.25±1.03 bVh2.5 mg compound (Vh)/20kg. of dog.146.25±1.98 bstandard2.5 mg doxazosin mesylate/20kg. of dog.116.12±1.54 cMeans within the same column bearing different superscripts are significantly at (p )(1)S. Gabriel; Ber., 36, 800, (1903).(2)P. Griess; Ber., 2, 415, (1869).(3)A. Weddige; J. Prakt Chem., 36 (2) , 141, (1887).(4)C. Paal and M. Busch; Ber., 22, 2683, (1889).(5) A. Scariabine, J. W. Constantine, H. J. Hess and W. K.McShane; Experientia, 24(11), 1150 (1968).(6) K. Karimian, K. Murthy and D. Hall; U. S. Pat., 5,675,006 (1997).United state patents could be downloaded from http://www.patentmatic.comor http://www.braindex.com/patent_pdf/(7) B.V. Shetty, L.A. Campanella, T. L. Thomas, M. Fedorchuk, T.A. Davidson, L. Michelson, H. Volz, S.E. Zimmerman E. J. Belair and A. P. Truant; J. Med. Chem., 13(5), 886, (1970).(8) T. Jen, B. Dienel, H. Bowman, J. Petta, A. Helt, and B. Loev; J. Med. Chem. 15(7), 727, (1972).(9) G. E. Hardtmann ; U. S. Pat. , 3,984,556, (1976),[through Chem.. Abstr., 86, 16701, (1977)].(10) H. Nagano, T. Mitiro, K. Noboru, I. Matsunaga, H. Nabata, Y. Ohba, K. Sakai, S. Hata and Y. Uchida; Eur. Pat. 89065, (1983), [through Chem.. Abstr., 100, 6547p (1984)]. European patents could be downloaded from http://www.patentmatic.com or http://www.braindex.com/patent_pdf/(11) J. De Cree, H. Verhaegen and J. Symoens; Lancet, 317, 1161(1981).(12) P. A. J. Janssen; J. Cardiovasc, Pharmacol., 7(suppl.7), S2 (1985), [through Chem.. Abstr., 103, 171860e (1986)].(13) M. C. Venuti ; U. S. Pat. 4,670,434, (1987), [through Chem.. Abstr., 107, 129041(1987)].(14) B. Erb, B. Rigo, R. Akue, B. Pirotte and D. Couturier; J. Heterocycl. Chem. , 37, 253, (2000).(15) A Kornicka, F. Saczewski. and M. Gdaniec; Molecules, 9, 86, (2004). Electronic journal; http:// www.mdpi.org.(16)E. Bencteux, R. Houssin and J. P. Henichart; J, Heterocycl. chem., 34, 1375,(1997).(17) R. S. Herbest, M. Fukouka and J. Baselga; J. Nat. Rev. Cancer, 4, 956(2004).(18) R.G. Griffin, S. Srinivasan, K. Bowman, A. H. Calvert, N. J. Curtin, D. R. Newell, L. C. Pemberton and B. T. Golding; J. Med. Chem., 41(26), 5247, (1998).(19)D. Raffa, G. Daidone, D. Schillaci, B. Maggio and F. Plescia; Pharmazie, , 54(4), 251,(1999).(20) G. Kulscar, T. Kalai, E, Osz, C. P. Sar , J. Jeko, B. Sumegi and K. Hideg; ARKIVOC, 5,121 (2003). Electronic journal; http://www.arkat-usa.org.(21) M. L. Gujral, K. N. Sareen and R. P. Kohila; Indian J. Med. Res., 45, 207 (1957), [through Chem.. Abstr., 51, 15787 h, (1957)].(22). G. B. Jackmann, V. Petrow and O. Stephenson; J. pharm. and pharmacol., 12, 529 (1960),[through Chem. Abstr., 55, 2657c(1961)].(23)G. E. Hardtmann, W. J. Houlihan; U. S. pat. 4,451,464 (1984), [through Chem.. Abstr., 101, 130707 , (1984)].(24)S. Nagai, T. Ueda, S. Sugiura, A. Nagatsu, N. Murackamai, J. Sakakibara, M. Fujita and Y. Hotta; J. Heterocycl. Chem., 35, 325, (1998).(25) A. A. Elhelby and M. H. Abdel-Wahab; Acta Pharm. 53, 127 (2003).(26)J. B. Koepfli, J. A. Brockman and J. Moffat; J. Am. Chem. Soc., 72, 3323 (1950).(27) S. Hirai, H. Kikuchi, H. Kim, K. Begum, Y. Wataya, H. Tasaka, Y. Miyazawa, K. Yamamoto and Y.Oshima,; J. Med. Chem., 46 (20), 4351 (2003).(28) K. M. Murav´eva, N. V. Arkhangel´ sk
|
|
|